Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropinirole CR as Adjunctive Therapy in Parkinson's Disease
NCT00381472Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2003
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Ropinirole CR with Placebo (2 arms). Primary endpoint: Mean change from baseline in awake time 'off' at 24 weeks. Started Jun 2003; status: completed.
02
Drugs
ropinirole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00381472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381472.